I-MOSQUIRIX, I-VACCINE EYEMPAKATHI EMALARIA (MALARIA)

Umuthi wokugoma umalaleveva wokuhlola umalaleveva, "Mosquirix", uthole ukuvunywa yi-European Medicines Agency ngoLwesihlanu. Okokuqala ezweni lezokwelapha noma ngabe i-serum, okwamanje isebenza kahle ngokwengxenye.
Lezi yizindaba ezinhle kakhulu futhi ezinhle kakhulu. NgoLwesihlanu ngoJulayi 24, umuthi wokugomela umalaleveva uthole “umbono omuhle” kwa-European Medicines Agency (EMA). Ibizwa nge- “Mosquirix” futhi yadalwa yi-drug GlaxoSmithKline (GSK) ukuvikela izingane ezincane, ikakhulukazi e-Afrika, ezihlaselwe yilesi sifo. Kungokokuqala ukuthi umuthi wokugoma wenzelwe i-parasite (Plasmodium falciparum, i-parasite kamalaleveva) hhayi ngokumelene negciwane noma amagciwane.

>> Gxila: “I-Malaria ibulala ingane njalo ngemizuzwana engu-30"

Lo "mbono omuhle" awusho ukumaketha ngokushesha kwe-serum, kepha kuyizindaba ezinhle kakhulu ezigulini, kungukukhanya kokuqala okuluhlaza ngaphambi kokuthola "ukuncoma" kokusetshenziswa kwenhlangano yomhlaba ye ezempilo (WHO).

"Unyaka nonyaka, cishe babalelwa ezigidini ezingama-200 abantu abaphethwe ngumalaleveva […] I-GSK ibilokhu izama ukuthuthukisa lo mgomo iminyaka engamashumi amathathu [….] Kungokokuqala ukuthi kube ne-serum elwa namagciwane", kukhombisa u-Elisabeth Van Damme, umphathi wezokuxhumana weqembu le-GSK egatsheni laseFrance abangama-000.

"IMINYAKA EMI-XNUMX EGCWELE UKUZE KUVULELE I-VACCINE" (ELISABETH VAN DAMME, GSK)

“Ukuvikela Isizotha”

I-GSK ayihlose ukumaketha ukugonywa kwe-malaria eYurophu, kodwa e-Afrika, ezindaweni ezinomlando kakhulu. Njalo ngonyaka, i-malaria inqanda abantu abangamatshumi amahlanu emhlabeni jikelele, kubandakanya iningi labantu base-Afrika.

Kepha kufanele uqaphele: okwamanje, Mosquirix akuyona ipanacea. "Umuthi wokugoma ukhonjiswe ukuthi usebenza [ekuvikeleni izifo] aze afike kuma-50%," kusho umphathi we-GSK. Kuphathelene nezingane ezisanda kuzalwa ezinamasonto ayisithupha kuya kwezinyanga eziyi-6 futhi ukusebenza kwawo kunciphe ngemuva konyaka owodwa, kusho i-EMA.

Ukuvikelwa “okunesizotha”, ngokwe-EMA, kepha kuvikela okufanayo.

Ngesikhathi sokushicilelwa kwale miphumela, uchwepheshe wezokwelapha osezindaweni ezishisayo, uNick White (Mahidol University, Thailand), ubephawule wathi: “Ekugcineni sinomuthi wokugomela umalaleveva osebenzayo, kepha awusebenzi njengathi ngethemba ekuqaleni ”.

"UMosquirix kuphela ngeke uqede umalaleveva"

"Ngokusekelwe emiphumeleni yocwaningo lokuhlolwa, i-CHMP [IKomidi leMithi Yezinto Zokusetshenziswa Kwabantu Kwe-EMA] yaphetha ngokuthi, yize kungasebenzi kahle, i -zuzo / ingozi yokulingana kwi-Mosquirix iyathandeka", kugcizelelwe ngoLwesihlanu l I-ejensi yaseYurophu eseLondon.

I-GSK, ehlelele ukumaketha umuthi wokugoma “ngezindleko” ngaphandle kokwenza inzuzo, iyabona ukuthi umkhiqizo wayo uwodwa akuyona “impendulo ephelele” ngokumelana nomalaleveva.

Umuthi wokugoma uzokwethula “ithuluzi elengeziwe emkhakheni wezempi” wokulwa nomalaleveva (amanetha omiyane, ama-insecticides…), kusho uDkt Fatoumata Nafo-Traoré, umqondisi omkhulu wenhlangano yamazwe omelana nomalaleveva “Roll Back umalaleveva ". "Ithathwe yodwa [...] IMosquirix ngeke iluqede umalaleveva".

Zingaphezu kuka-1 300 izingane ezibulawa umalaleveva nsuku zonke. Ngokusho kwe-WHO, abantu abangama-627 bafa ngonyaka ka-000 beqhamuka umalaleveva, ikakhulukazi e-Afrika (2013%) futhi ikakhulukazi izingane ezingaphansi kweminyaka engu-90 (5%).

Nge-AFP

http://www.france24.com/fr/20150725-paludisme-afrique-vaccin-malaria-agence-europ%C3%A9enne-medicament-GSK-OMS-commercialisation-sante-serum-mosquirix%20